Q1 2024 · 13F-HR
Sarissa Capital Management LPholdings as filed
Filed 2024-05-15 · accession 0000899140-24-000608
$571.6M
Reported value
10
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $142.8M | 25.0% | 16,390,000 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $138.7M | 24.3% | 643,000 | Common | SOLE |
| 45781M101 | INVA | INNOVIVA INC | $110.9M | 19.4% | 7,277,000 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $80.8M | 14.1% | 1,103,282 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $47.8M | 8.36% | 346,426 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $22.1M | 3.87% | 24,850,623 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $21.0M | 3.68% | 300,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $5.6M | 0.97% | 1,094,168 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $1.5M | 0.26% | 618,000 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $533,327 | 0.09% | 185,183 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.